Synaptogenix, Inc. (NASDAQ:SNPX) Short Interest Down 66.7% in December

Synaptogenix, Inc. (NASDAQ:SNPX) was the target of a large decrease in short interest in the month of December. As of December 15th, there was short interest totalling 2,400 shares, a decrease of 66.7% from the November 30th total of 7,200 shares. Approximately 0.2% of the shares of the company are short sold. Based on an average daily trading volume, of 22,600 shares, the short-interest ratio is presently 0.1 days.

Synaptogenix Stock Down 3.9 %

SNPX stock traded down $0.13 during mid-day trading on Friday, reaching $3.17. 19,303 shares of the stock traded hands, compared to its average volume of 35,694. The business has a 50-day moving average of $2.91 and a two-hundred day moving average of $3.44. Synaptogenix has a 52 week low of $2.32 and a 52 week high of $8.78.

Synaptogenix (NASDAQ:SNPX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($4.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.95) by ($2.63).

About Synaptogenix

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.